University of Hawai‘i at Manoa Homepage
Hawaiian Fern

University of Hawaii Cancer Center

News Highlights

September 22, 2014

Serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML

By Chantal Jackson

HONOLULU, HI- University of Hawai'i Cancer Center's Dr. Wei Jia's collaborative article regarding acute myeloid leukemia (AML) has received the Cancer Center's September 2014 award as the "Publication of the Month." Dr. Wei Jia has acted as corresponding author to a report which has identified a panel of markers used in the identification of intermediate group prognosis in individuals with AML.

Acute myeloid leukemia (AML) is a group of hematological malignancies. AML patients can be divided into groups associated with variable health outcomes: favorable, intermediate, and unfavorable. While the favorable and unfavorable groups demonstrate clear prognoses, the outcome of the intermediate group is not as straightforward.

In collaboration with Dr. Sai-Juan Chen and Dr. Zhu Chen in Shanghai, China, Dr. Jia and his team used serum metabolic profiling as a measure, and subsequently determined that the profiles of AML patients were markedly different from those of healthy controls. Metabolite markers were differently expressed in serum which contributed to these different profiles.

Dr. Wei Jia explains: "In patients with AML, physicians can divide between favorable, intermediate, and unfavorable with associated prognostic outcomes. It would be valuable to those in the intermediate group to be able to use these molecular biomarkers to determine whether or not they face a poor prognosis. Based on the prognostic identification of intermediate group AML patients, a treatment plan can be better established."

Through this report, the authors support the use of serum metabolites and metabolic pathways as novel prognostic markers and potential therapeutic targets for AML. By incorporating these markers, intermediate group prognoses can be determined, and ultimately a treatment plan can be better established for low-survival rate patients. The study: "A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value" is published in the September 4, 2014 edition of Blood.

Back to HomeĀ»

News Highlights

September 30, 2014

Phil Olsen

Makiki man active in fight against cancer

Phil Olsen began a support group for men during his ongoing battle with prostate cancer

By Nina Wu - Honolulu Star Advertiser

When Phil Olsen of Makiki was diagnosed with prostate cancer in 1989, the future seemed dire.

He underwent several painful biopsies to pinpoint the location of the tumor in his prostate, a walnut-size gland below the bladder. He was given the option of orchiectomy, or the surgical removal of his testes, but said no thanks.

Smartphone App

At the time, he was working as a corporate pilot for Alexander & Baldwin.

Three years after the diagnosis, Olsen learned the cancer had spread to his bones. His doctor advised him to get his affairs in order.

"I saw the Grim Reaper," he said.

Prostate cancer is second only to lung cancer as a leading cause of cancer-related deaths among men in the U.S., according to the American Cancer Society. It is one of the top five cancers that kill males in Hawaii, according to the University of Hawaii Cancer Center, which estimates about 800 cases of invasive prostate cancer are diagnosed in the state each year.

But Olsen, 83, has beaten the odds.

The former UH administrator and retired flight instructor is not only managing to live with cancer, but is proactively battling it on numerous fronts ā€” not the least of which was a $25,000 donation last week to the UH Cancer Center for prostate cancer research.

"I really am impressed with the potential of the university having a cancer center that becomes a true star performer in research, treatment and prevention of all cancers," he said. "I think we're within striking distance of coming up with some solid cures and preventions."

The center brought Charles Rosser, former chief of urologic oncology at the MD Anderson Cancer Center in Orlando, Fla., on as a research program director in January, a move Olsen sees as important in creating a comprehensive cancer research center in Hawaii.

When it came to choosing a path of treatment for his cancer, Olsen took the route less traveled.

He chose not to undergo surgery or chemotherapy. Instead, he went through external beam radiation for about a year, followed by androgen deprivation therapy to reduce male hormone levels, which he continues today. Olsen also sought second opinions, eventually receiving treatment from a prostate cancer specialist in Marine Del Ray, Calif.

"I think we've got to keep pushing the envelope," he said. "We've got to question the status quo and make new options where they don't exist."

Smartphone App

The former marathon runner took up meditation and continued exercising. When he could no longer run, he walked.

Today he walks about four miles several times a week, sometimes accompanied by a friend. Among his companions are cardiologist and Honolulu Marathon founder Jack Scaff, who first detected Olsen's abnormal prostate during a routine exam.

To help others facing prostate cancer, Olsen in 2005 founded the Hawaii Prostate Cancer Coalition, a nonprofit advocacy and support group linked to a national organization. He said he used support groups for women with breast cancer as a model for the organization. Men tend to keep their cancer to themselves but would benefit from sharing, according to Olsen.

"They need to talk about it because that's the only way to gain any wisdom about the nature of their disease," he said. "It's a very complex disease, and, furthermore, it's of great value to men's families and loved ones. We welcome them to the support groups."

Recently, Olsen underwent a scan at the Queen's Medical Center with a state-of-the art imaging tool, the 3 Tesla MRI, to monitor his health and is inspired by the medical technology available today. In his battle against cancer, he has never given up hope.

"We've come a long way," he said. "I hope it leads to more people following suit and contributing not only their time and efforts, but also their financial support in a successful battle against prostate cancer."


News Highlights

October 27, 2014

Phil Olsen

Putting the Chill on Cancer

By Stacy Wong

The UH Cancer Center received a $30,000 donation from Cooling Cancer to fund cancer research in Hawaii. Drew Santos, president of Admor HVAC Products, Inc., one of Hawaii's largest distributors of air conditioning equipment and accessories, founded Cooling Cancer after his own father died of cancer and other people in his company also lost loved ones to the disease. The recent donation is the second in two years, and brings the total donated from Cooling Cancer's golf tournaments to $55,000. Cooling Cancer's Vice President is Charles Young; Secretary, Corey Correa, and Treasurer, Shirley Santos.


News Highlights

September 23, 2014

Lana Garmire, PhD, recently awarded $1.8 million for two 5-year NIH Grants

Lana Garmire, PhD, at the University of Hawaii Cancer Center (UHCC) has recently been awarded two 5-year NIH grants. One is a K01 career award for new investigators to conduct research in Big Data Science. The amount of the award is for $934,000 for the study of single cancer cell heterogeneity using the integrated bioinformatics approach. Dr. Garmire is the Project Leader of one of the four projects in a program project grant called the COBRE P20. The principal investigator (PI) of the COBRE is Dr. Steve Ward at the UH John A, Burns School of Medicine. For her project, Dr. Garmire was awarded $875,000 to investigate the effect of maternal obesity on offspring cancer risk through analyzing the methylome and transcriptome of the cord blood stem cells. Dr. Garmire is a tenure-track Assistant Researcher (equivalent to Assistant Professor) who received her PhD in computational biology from UC Berkeley. She joined the UHCC in December 2012, and in less than 2 years has won multiple grants from several funding agencies.

Back to HomeĀ»